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Aspergillus  viridinutans,  a  mold  phenotypically  re-
sembling A. fumigatus,	was	identified	by	gene	sequence	
analyses from 2 patients. Disease was distinct from typical 
aspergillosis, being chronic and spreading in a contiguous 
manner across anatomical planes. We emphasize the rec-
ognition of fumigati-mimetic molds as agents of chronic or 
refractory aspergillosis.
A
spergillus fumigatus is the most common cause of in-
vasive aspergillosis afflicting various immunocompro-
mised patients. We report 2 cases of documented invasive 
disease in children in the United States caused by A. viridi-
nutans, a fumigati-mimetic mold, which produced clinical 
manifestations distinct from A. fumigatus.
The Patients
Patient 1 was a 14-year-old boy with p47phox-deficient 
chronic  granulomatous  disease.  He  had  Staphylococcus 
aureus liver abscesses at ages 5 and 10 years, Burkhold-
eria cepacia complex pneumonia at age 6 years, and Ser-
ratia marcescens pneumonia at age 12 years. In February 
2004, while the patient was receiving itraconazole prophy-
laxis, right-sided chest pain and fever developed. A com-
puted tomography (CT) scan showed a 2-cm right middle 
lobe nodule adjacent to the cardiac border and mediastinal 
lymphadenopathy abutting the superior vena cava and ante-
rior pericardium (Figure 1). Lymph node biopsy yielded a 
mold morphologically identified as A. fumigatus. Treatment 
with voriconazole was initiated. Repeat imaging 1 week lat-
er showed slight enlargement of the mediastinal mass. One 
month later, there was continued enlargement of the lung 
nodule and mediastinal adenopathy with necrosis. Caspo-
fungin was added. Two weeks later, a new right middle lobe 
infiltrate was noted. Antifungal therapy was changed to pos-
aconazole. Over the next 2 months, there was expansion of 
the right lung infiltrates and lymphadenopathy. Treatment 
was modified to posaconazole and caspofungin. Serial im-
aging over the next 3 weeks showed regression of the lung 
consolidations  and  mediastinal  mass.  Four  months  later, 
with ongoing resolution of the thoracic disease, the patient 
began receiving a maintenance dosage of posaconazole. As 
of 5 years later, he had experienced no recurrence.
Patient  2  was  an  8-year-old  boy  with  hyperimmu-
noglobulin-E (Job) syndrome due to mutation in signal 
transducer  and  activator  of  transcription-3  in  whom  a 
right-sided pulmonary abscess developed and failed to im-
prove after 1 month of antibacterial therapy. New left lung 
nodules were biopsied and specimens yielded a mold mor-
phologically identified as A. fumigatus. During 3 months 
of treatment with voriconazole, the bilateral pulmonary le-
sions cavitated. Two months later, left lower lobe wedge 
resection  yielded  the  same  mold.  Diaphragmatic  injury 
required primary closure with sutures. One month later, 
enlargement  of  the  residual  left  lung  lesions  prompted 
change  in  therapy  to  amphotericin  B  and  caspofungin. 
Following the patient’s transfer to the National Institutes 
of Health, imaging showed left apical and lower lobe cavi-
tary masses, left pleural mass and effusion, and a right up-
per lung cavity with nodule. Samples taken from the left 
lower cavity and pleura demonstrated septated branching 
hyphae; specimens grew a mold resembling A. fumiga-
tus.  Amphotericin  B–related  nephrotoxicity  prompted 
change  of  treatment  drug  to  posaconazole.  Tissues  ob-
tained through subsequent surgical debridements of lung, 
pleural,  diaphragmatic,  and  subpulmonic  abscesses,  left 
lower lobe segmentectomy, and decortication all grew a 
mold morphologically consistent with A. fumigatus. The 
patient’s medical regimen was changed to posaconazole, 
caspofungin,  and  flucytosine.  Persistent  pleural  tube 
drainage yielded the same fungus, despite treatment with 
amphotericin  B  and  granulocyte  intrapleural  infusions. 
Systemic granulocyte infusions, adjunctive granulocyte-
colony stimulating factor, and interferon-γ led to transient 
stabilization of disease. However, progressive splenic ab-
scess formation contiguous with the diaphragm was noted 
(Figure 2). Seven months later, Guillain-Barré syndrome 
without a clear cause developed in the patient. The patient 
died of progressive respiratory failure with aspiration of 
abscess cavity content. Autopsy demonstrated extensive 
fungal abscesses in the lungs and left pleural space that 
extended into the airways, diaphragm, and spleen.
Isolates were initially identified by morphologic crite-
ria using standard clinical mycology laboratory media and 
incubation conditions. Subsequently, multilocus sequence 
analyses  were  performed  and  targeted  the  internal  tran-
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scribed spacer (ITS) 1 and 2 regions flanking 5.8S rDNA, 
(partial) β-tubulin gene (benA), and (partial) calmodulin 
gene as previously described (1–4). Sequences were as-
sembled  by  using  Lasergene  version  7.0  (DNASTAR; 
www.dnastar.com),  compared  with  sequences  in  Gen-
Bank by using BLAST (www.ncbi.nlm.nih.gov/BLAST), 
and realigned relative to best-matched sequences by us-
ing MegAlign (DNASTAR). Sequencing of ITS assigned 
the isolates to Aspergillus section Fumigati but could not 
provide  further  intrataxon  discrimination.  The  β-tubulin 
sequence from patient 1 had 96.3% and 99.5% similarity 
with A. viridinutans type strain IMI062875T (AF134779) 
and  strain  IMI182127  (AF134777),  respectively.  Three 
isolates from patient 2 were tested, demonstrating 96.3% 
and  98.4%  similarity  with  A.  viridinutans  type  strain 
CBS127.56T  (AF134779)  and  NRRL6106  (AF134778), 
respectively.  The  calmodulin  sequences  from  patient  1 
and patient 2 demonstrated 99.8% and 99.0% similarity, 
respectively, to A. viridinutans IMI182127 (DQ094888). 
The 2 patients’ isolates were 98.6% similar to each oth-
er. The strains were designated NIHAV1 (from patient 1) 
and NIHAV2 (from patient 2). The deduced amino acid 
sequence from NIHAV1 had 100% similarity with strain 
IMI182127 (AF134777); NIHAV2 differed by 1 aa with 
strain  NRRL6106  (AF134778).  NIHAV1  and  NIHAV2 
differed by 1 aa (98.8% similarity). Sequences obtained for 
NIHAV1 benA, NIHAV1 calmodulin, NIHAV2 benA, and 
NIHAV2 calmodulin have been deposited in GenBank un-
der accession nos. GQ144441, GQ144442, GQ144440, and 
GQ144443, respectively.
Antifungal drug susceptibility testing was performed 
by broth microdilution at the Fungus Testing Laboratory, 
University of Texas Health Sciences Center, using Clini-
cal Laboratory Standards Institute’s contemporary method 
M38A (Table). Isolates underwent extended incubation to 
ensure sufficient conidia for testing. Although no clinical 
interpretive breakpoints are established, most clinical iso-
lates identified as A. fumigatus have MICs to amphotericin 
B and voriconazole <0.5–1 mg/L (5–7). The A. viridinutans 
isolates, however, demonstrated significantly higher MICs 
to amphotericin B and voriconazole, agents recommended 
as first-line therapy for treatment of aspergillosis (8). This 
in vitro resistance may explain in part the refractory disease 
seen clinically. Furthermore, synergistic studies of isolates 
from patient 2 with the combination of either posaconazole 
and terbinafine or amphotericin B and terbinafine produced 
an indifferent effect.
Conclusions
Differentiation of species within Aspergillus section 
Fumigati using phenotypic features alone is difficult. Our 
isolates resembled A. fumigatus but demonstrated slower 
growth at 37°C and markedly reduced sporulation. Based 
on multilocus sequence analyses, however, these isolates 
are A. viridinutans, a mold phenotypically resembling but 
phylogenetically distinct from A. fumigatus. Although the 
ITS region failed to distinguish these isolates from A. fu-
migatus, weak intrataxon discriminatory capacity has been 
previously reported for this locus (9). β-tubulin and calm-
odulin sequences confirmed its identification as A. viridi-
nutans. Sequence divergence within our isolates is con-
sistent with findings from previous studies demonstrating 
intraspecific genetic variability within the A. viridinutans 
species (10–12).
A. viridinutans was originally isolated from rabbit dung 
in Australia and has since been identified in soil samples 
globally (12,13). Although A. viridinutans has been reported 
from retrospective analysis of culture collections (9–11), its 
clinical relevance has not been defined. These cases demon-
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Figure	1.	Computed	tomography	scan	of	thorax	showing	extension	
of infection with Aspergillus viridinutans into mediastinal structures 
(arrow).
Figure	 2.	 Computed	 tomography	 scan	 showing	 infection	 with	
Aspergillus viridinutans, originating in the lungs, extending into the 
diaphragm (arrowhead), and producing hypodense splenic lesions 
(arrow).strate that A. viridinutans can cause a distinct form of asper-
gillosis, characterized by chronicity, propensity to spread in 
a contiguous manner across anatomical planes, and relative 
refractoriness  to  antimycotic  drugs.  In  contrast,  invasive 
aspergillosis affecting neutropenic chemotherapy or trans-
plant patients is typically an acute disease with predilection 
for  angioinvasion  and  hematogenous  dissemination;  suc-
cessful response to antifungal therapy most commonly oc-
curs within the first 6 weeks of treatment (14). However, A. 
viridinutans infections in 2 patients with distinct primary 
immunodeficiencies suggest that these clinical phenomena 
reflect inherent pathogenic features of the mold, rather than 
manifestations due to a specific immune defect. A similar 
constellation has been described for another cladistically re-
lated fumigati-mimetic, Neosartorya udagawae, in patients 
with  chronic  granulomatous  disease  or  myelodysplasia 
(15), which may suggest pathogenetic differences between 
subgroups within section Fumigati. Thus, genotypic-based 
identification of fumigati-mimetic fungi may have implica-
tions for clinical course and management.
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Table.	Antifungal	drug	susceptibility	results	of	Aspergillus viridinutans isolates relative to A. fumigatus	reported	at	48	hours*	
Isolate
Amphotericin	B	
MIC,	mg/L	
Itraconazole
MIC,	mg/L	
Voriconazole
MIC,	mg/L	
Posaconazole
MIC,	mg/L	
Caspofungin
MEC,	mg/L	
Terbinafine
MIC,	mg/L	
Patient	1	 4 1 1 0.06 0.25 ND
Patient	2†	 2–8 8 2–4 <0.016–0.5 0.06–0.25 0.125–1
A. fumigatus	B-5233‡	 0.5 0.5 0.5 0.125 0.25 2
*MEC,	minimal	effective	concentration;	ND,	not	determined.	
†Composite	results	of	3	isolates from the patient. 
‡Clinical	isolate	from	a	patient	with	a	fatal	case	of	aspergillosis	(courtesy	of	K.	J.	Kwon-Chung,	National	Institute	of	Allergy and Infectious Diseases, 
Bethesda,	MD,	USA).	